Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-482P is a *pseudogene* belonging to the family of U6 small nuclear RNA genes. U6 snRNA is a critical non-coding RNA component of the major spliceosome, responsible for mRNA splicing in eukaryotic cells[3]. However, **pseudogenes** such as RNU6-482P have mutations or sequence differences that prevent them from producing functional snRNA products. These loci are typically regarded as non-functional vestiges of evolutionary history, created through gene duplication or retrotransposition events, and are **not** considered therapeutic targets[2][5]. While some pseudogenes can be transcribed and have regulatory roles (e.g., antisense RNA, competing endogenous RNA), this is not universally true, and there is no evidence RNU6-482P exhibits such activity[4]. Pseudogenes may sometimes complicate genetic analysis, but as a class, they do not encode proteins and do not participate directly in cellular functions or serve as drug targets.
None (not a drug target; pseudogenes do not encode proteins or established molecular functions)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 482, pseudogene (RNU6-482P).